IVN-CAT-001A Performance of CAST With Different Allergens in Patients With Cat Dander Allergy - Tabular View

Tracking Information

First Received Date ^ICMJE

February 11, 2008

Last Updated Date

November 19, 2008

Start Date ^ICMJE

September 2005

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Original Primary Outcome Measures ^ICMJE

Change History

Complete list of historical versions of study NCT00620880 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

IVN-CAT-001A Performance of CAST With Different Allergens in Patients With Cat Dander Allergy

Official Title ^ICMJE

Performance of CAST With Different Allergens in Patients With Cat Dander Allergy

Brief Summary

Primary objective of the trial:

To determine at which concentration the fusion protein MAT Fel d1 degranulates basophils of cat dander allergic patients, in comparison to a cat dander extract and to Fel d1 alone

Detailed Description

Study Phase

Study Type ^ICMJE

Observational

Study Design ^ICMJE

Prospective

Condition ^ICMJE

Allergy to Cats

Intervention ^ICMJE

Behavioral: Blood sample

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Completion Date

September 2006

Primary Completion Date

Eligibility Criteria ^ICMJE

Inclusion criteria: 1. Patient with Cat Dander Allergy evidenced by positive history 2. Age: 18 to 75 years

Exclusion criteria: 1. Use of oral corticosteroids, Chromoglycin, Ketotifen, or any immunosuppressive drugs within the last 2 months 2. Psychiatric disorder resulting in malcompliance 3. Neg. IgE to Cat dander

Gender

Both

Ages

18 Years to 75 Years

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

Switzerland

Administrative Information

NCT ID ^ICMJE

NCT00620880

Responsible Party

University Hospital Zürich, University of Zurich

Study ID Numbers ^ICMJE

IVN-CAT-001A

Study Sponsor ^ICMJE

University of Zurich

Collaborators ^ICMJE

ImVision AG

Investigators ^ICMJE

Study Director:

01 Studienregister MasterAdmins

UniversitaetsSpital Zuerich

Information Provided By

University of Zurich

Verification Date

November 2008

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP